Which anti-CGRP monoclonal antibody is marketed as Emgality?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which anti-CGRP monoclonal antibody is marketed as Emgality?

Emgality refers to the anti-CGRP monoclonal antibody galcanezumab. It works by binding the CGRP peptide itself, preventing CGRP from activating its receptor and thereby reducing migraine frequency. The other approved anti-CGRP antibodies have different brand names and targets: erenumab blocks the CGRP receptor (Aimovig), while fremanezumab and eptinezumab target the CGRP ligand (Ajovy and Vyepti, respectively). Emgality is given as a monthly subcutaneous injection for migraine prevention in adults (and also has approval for episodic cluster headache in adults).

Emgality refers to the anti-CGRP monoclonal antibody galcanezumab. It works by binding the CGRP peptide itself, preventing CGRP from activating its receptor and thereby reducing migraine frequency. The other approved anti-CGRP antibodies have different brand names and targets: erenumab blocks the CGRP receptor (Aimovig), while fremanezumab and eptinezumab target the CGRP ligand (Ajovy and Vyepti, respectively). Emgality is given as a monthly subcutaneous injection for migraine prevention in adults (and also has approval for episodic cluster headache in adults).

More practice questions